Faes Farma (BME:FAE) is back in focus after reporting nine-month 2026 results, with sales of €551.94 million and revenue of €563.54 million, alongside net income of €74.13 million.
The latest nine month update has landed against a backdrop of mixed price action for Faes Farma, with the share price gaining 10.01% over the past 90 days but declining 4.21% year to date, while a long term total shareholder return of 72.99% over five years signals momentum that has built gradually over time.
Scan how Faes Farma compares with other handpicked healthcare and pharma businesses by pulling up the 201 high quality undervalued stocks, which combines stronger balance sheets with solid cash generation.
Faes Farma’s latest swing, with a gain over the past quarter but a decline year to date, sits between a stronger top line and changing mood music in the market. Which side does the current valuation really echo?
Most Popular Narrative: 6.6% Undervalued
Faes Farma is priced at €5.00 against an analyst consensus Narrative fair value of about €5.36, which points to a modest discount based on forecasts compiled in the analyst consensus Narrative on Simply Wall St and the revenue and earnings path those analysts are using.
The integration of SIFI and Edol is adding ophthalmology as a new therapeutic platform, which expands Faes Farma's addressable market and can support a broader revenue base and scale benefits for EBITDA and earnings.
See why 4 investors see Faes Farma as 7% undervalued.
Result: Fair Value of €5.36 (UNDERVALUED)
Still, the Faes Farma story hinges on Latin America carrying much of the growth burden and on Bilastine generics not eroding the allergy franchise too quickly.
Find out about the key risks to this Faes Farma narrative.
Next Steps
Mixed signals on Faes Farma so far. If you want to move quickly and build your own view from the ground up, start by weighing its 3 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Faes Farma?
If Faes Farma has sharpened your focus, broaden your opportunity set now by scanning other ideas that match your risk tolerance and income goals.
- Target steadier rides by reviewing a curated group of resilient businesses in the 209 resilient stocks with low risk scores that keep risk scores in check.
- Pursue reliable income streams by assessing companies in the 215 dividend fortresses that pair higher yields with a focus on durability.
- Get ahead of the crowd by scanning the 563 high quality undiscovered gems that combine strong fundamentals with low market attention.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com